MSB 5.50% $1.38 mesoblast limited

Ann: P3 trial initiated, positive 24 mth P2 results in back pain, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 524 Posts.
    lightbulb Created with Sketch. 1511
    "FDA approval for surgical therapies requires concomitant improvement in both pain and function" (per previous MSB info).

    1st time 24 months results presented re 100 patient trial... quite significant IMO ( we previously knew 12 months only).
    Based on the 24 month results - FDA approves Phase III commencement.

    Good Luck Holders.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.